ViiV planning submissions this year for two-drug HIV regimen

ViiV said it plans to submit regulatory applications this year for a once-monthly two-drug regimen comprising cabotegravir and Johnson & Johnson's Edurant rilpivirine to treat HIV-1 infection.

ViiV Healthcare Ltd. (Brentford, U.K.) disclosed its plans when the company presented detailed data from the open-label Phase III ATLAS and FLAIR trials of the combo as maintenance treatment of HIV-1-infection at the Conference on Retroviruses and Opportunistic Infections in Seattle...